Clinical Supplies Management
A Connecticut-based investment firm that focuses primarily on the health care industry, Great Point Partners (GPP) has invested its clients capital since its formation in 2003. Clinical Supplies Management (CSM), one of Great Point Partners’ portfolio companies, announced its acquisition of a second European company in January 2017.
Following its purchase of Theorem Clinical Supply, which is a Frankfurt-based health care business, CSM has acquired B&C Group. Headquartered in Brussels, Belgium, B&C provides clinical trial supplies, in addition to biomedical sample services.
Both acquisitions have expanded CSM’s European footprint, offering it two full-time facilities on the continent. Further, CSM’s biomedical sample services have expanded due to the acquisitions.
As part of the most recent acquisition, B&C’s CEO Phillipe Van der Hofstadt will lead CSM’s European activities going forward. In speaking about the opportunity, Van der Hofstadt noted that the acquisition of B&C formalized a longstanding partnership between it and CSM, adding that CSM is now perfectly poised to offer greater value to its customers.
Great Point Partners
A Connecticut firm with an investment portfolio of health care companies spanning two continents, Great Point Partners seeks out financially sound businesses in expanding markets. In October of 2016, Great Point Partners expanded its footprint by investing in Clinical Supplies Management (CSM).
Established by a pharmacist two decades ago, CSM provides biotechnology, life science, and pharmaceutical companies with a host of services spanning drug packaging and logistics. The company has grown over the years from offering niche assistance in “returns and reconciliations” to meeting clients’ full range of materials management needs for clinical trials.
A principal of Great Point Partners described this infrastructure-focused investment as making sense from the perspective of supporting CSM’s efforts to expand in an evolving industry. The investment funds will help finance an “accelerated growth strategy” with a global focus.
In January 2017, this approach bore fruit as CSM undertook the acquisition of Belgian B&C Group, the second recent addition to its European portfolio.
Alliance Biomedical Research
Founded in 2003, Great Point Partners is a healthcare investment firm with. Based in Greenwich, Connecticut, Great Point Partners (GPP) has a team of 28 professionals investing primarily in North America and additionally in Western Europe.
In September 2016, GPP announced a growth recapitalization of Alliance Biomedical Research (ABR), a clinical trial research business based in Greenville, South Carolina. Pharmaceutical and biotechnology companies contract with ABR to conduct Phase II through Phase IV clinical studies, which involves recruiting eligible patients to test drugs, monitoring results, complying with FDA and sponsor standards, and giving an account of their results to the clients.
Founded in 2004 with a vision of becoming the leading clinical trial research company, ABR has been able to grow organically from a single location to 11 sites. GPP’s investment will enable ABR to improve its infrastructure and execute a growth strategy comprising the development of new facilities and strategic tuck-in acquisitions.
With the new partnership, Jim Petrilla, founder of BioAgilytix, will join ABR as the new chief executive officer and Richard Vaillant, former CFO at Cytovance Biologics, will be ABR’s new CFO.
Professional Orthopedic and Sports Physical Therapy
Based in Connecticut, Great Point Partners (GPP) has an investment approach that makes equity capital-funded acquisitions of health care organizations across North America and Western Europe. In July, 2016, Great Point Partners announced a pair of acquisitions through Professional Physical Therapy (ProPT), a GPP portfolio company.
With the acquisition of PRO Physical Therapy and Achieve Sports Medicine & Rehab, the Connecticut firm now has a trio of new New Jersey clinics spanning Wyckoff, Randolph, and Waldwick. These bring the number of 2016 ProPT tuck-in acquisitions up to seven, with the company’s resources extending to nearly 90 outpatient locations across the Northeast. This consolidates the firm’s status as one of the leading physical therapy providers region-wide.
A ProPT executive described the acquisition as making strategic sense in enabling robust partnerships among knowledgeable, well-established local practitioners. With this expanded roster of physical, hand, and occupational therapists in place, patients will receive enhanced care tailored to their specific rehabilitative goals.
Accountable Care Organizations
Based in Connecticut, Great Point Partners invests in a variety of health care businesses across the globe. Among Great Point Partners’ areas of focus are consumer health and accountable care organizations (ACOs).
ACOs embody a network of health care providers and institutions that voluntarily provide medical attention to patient populations. ACOs operate under the premise that all patients should receive proper care. To improve efficiency, ACOs must address the following factors:
– Cultural – Patient-centric ACOs acknowledge and integrate different cultures into its care processes. Although ACOs are clinician-led, these organizations recognize the role of patients in the health care system.
– Clinical staff – The shortage of primary care providers challenges the efficiency of ACOs. The long-term solution to this problem is to establish a multidisciplinary approach that addresses inequalities among medical specialties.
– Administrative resources – Dedicating adequate administrative resources to actuarial and financial services contributes to the efficiency of ACOs. These resources are primarily responsible for managing the alignment of the patient population.
Great Point Partners
Connecticut-based Great Point Partners has been an active investor in pharmaceutical infrastructure since 2010. Great Point Partners has made investments in multiple companies; Caption Proteomics, Cytovance Biologics, Corrona and Softbox.
Pharmaceutical infrastructure is key in serving the logistical needs of the medical industry. The daunting task of using limited resources often leads companies to outsource key areas of their logistical pipeline. These can include maintenance on equipment, transportation and shipping needs for finished products, and managing energy services for manufacturing facilities.
These investments in infrastructure occur throughout the supply chain for biotech companies. Everything from patient records to pharmaceutical manufacturing provides ample opportunity for growth and the potential for significant returns for savvy investors.